BioAmber (BIOA) Files $150M IPO
BioAmber, Inc. (Nasdaq: BIOA)(NYSE: BIOA) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $150 million. BioAmber plans to list under the ticker 'BIOA,' but hasn't specified an exchange.
The offering is being made through Goldman, Sachs & Co., Credit Suisse, Barclays Capital, Stifel Nicolaus Weisel, and Pacific Crest Securities.
BioAmber is a next-generation chemicals company, whose proprietary technology platform combines industrial biotechnology, an innovative purification process and chemical catalysis to convert renewable feedstocks into chemicals that are cost-competitive replacements for petroleum-derived chemicals.
The offering is being made through Goldman, Sachs & Co., Credit Suisse, Barclays Capital, Stifel Nicolaus Weisel, and Pacific Crest Securities.
BioAmber is a next-generation chemicals company, whose proprietary technology platform combines industrial biotechnology, an innovative purification process and chemical catalysis to convert renewable feedstocks into chemicals that are cost-competitive replacements for petroleum-derived chemicals.
Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, Stifel Nicolaus, Barclays, Pacific Crest SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!


Tweet
Share